A Prospective, Open-label, Multicenter Study With Blinded Over-reading Characterizing the Efficacy and Safety of 99mTc-EC-DG in the Evaluation of Coronary Artery Disease (CAD)
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Tc 99m ethylenedicysteine deoxyglucose (Primary) ; Tc 99m sestamibi
- Indications Coronary artery disease
- Focus Diagnostic use
- Sponsors CellPoint
Most Recent Events
- 01 Apr 2025 Planned End Date changed from 1 Jan 2023 to 1 Apr 2026.
- 01 Apr 2025 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.
- 01 Apr 2025 Planned initiation date changed to 10 May 2025.